Correlation Between Grace Therapeutics, and Zenas BioPharma,

Can any of the company-specific risk be diversified away by investing in both Grace Therapeutics, and Zenas BioPharma, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Grace Therapeutics, and Zenas BioPharma, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Grace Therapeutics, and Zenas BioPharma, Common, you can compare the effects of market volatilities on Grace Therapeutics, and Zenas BioPharma, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Grace Therapeutics, with a short position of Zenas BioPharma,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Grace Therapeutics, and Zenas BioPharma,.

Diversification Opportunities for Grace Therapeutics, and Zenas BioPharma,

-0.6

Correlation Coefficient

Grace Therapeutics,  Zenas BioPharma,

Excellent diversification

The 3 months correlation between Grace and Zenas is -0.6. Overlapping area represents the amount of risk that can be diversified away by holding Grace Therapeutics, and Zenas BioPharma, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Zenas BioPharma, Common and Grace Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Grace Therapeutics, are associated (or correlated) with Zenas BioPharma,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Zenas BioPharma, Common has no effect on the direction of Grace Therapeutics, i.e., Grace Therapeutics, and Zenas BioPharma, go up and down completely randomly.

Pair Corralation between Grace Therapeutics, and Zenas BioPharma,

Given the investment horizon of 90 days Grace Therapeutics, is expected to generate 0.8 times more return on investment than Zenas BioPharma,. However, Grace Therapeutics, is 1.25 times less risky than Zenas BioPharma,. It trades about 0.07 of its potential returns per unit of risk. Zenas BioPharma, Common is currently generating about -0.13 per unit of risk. If you would invest  225.00  in Grace Therapeutics, on September 20, 2024 and sell it today you would earn a total of  155.00  from holding Grace Therapeutics, or generate 68.89% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	27.42%
Values	Daily Returns

Grace Therapeutics,  vs.  Zenas BioPharma, Common

Grace Therapeutics,

Risk-Adjusted Performance

10 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Grace Therapeutics, are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak fundamental indicators, Grace Therapeutics, exhibited solid returns over the last few months and may actually be approaching a breakup point.

Zenas BioPharma, Common

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Zenas BioPharma, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Etf's forward indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the ETF investors.

Pair Trading with Grace Therapeutics, and Zenas BioPharma,

The main advantage of trading using opposite Grace Therapeutics, and Zenas BioPharma, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Grace Therapeutics, position performs unexpectedly, Zenas BioPharma, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Zenas BioPharma, will offset losses from the drop in Zenas BioPharma,'s long position.

The idea behind Grace Therapeutics, and Zenas BioPharma, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.